Search results
Results from the WOW.Com Content Network
Sanofi-Aventis – Sanofi-Aventis Ltd; Sanofi Pasteur – Sanofi Pasteur MSD Ltd; Sanofi-Synthélabo – Sanofi-Aventis Ltd; Schering-Plough – Schering-Plough Ltd; Schwarz – Schwarz Pharma Ltd; Searle – Pfizer Ltd; Seqirus - was Novartis Vaccines Serono – Serono Pharmaceuticals Ltd; Servier – Servier Laboratories Ltd; Shire – Shire ...
Benzbromarone is a uricosuric agent and non-competitive inhibitor of xanthine oxidase [1] used in the treatment of gout, especially when allopurinol, a first-line treatment, fails or produces intolerable adverse effects.
Sanofi S.A. is a French multinational pharmaceutical and healthcare company headquartered in Paris, France. The corporation was established in 1973 and merged with Synthélabo in 1999 to form Sanofi-Synthélabo. In 2004, Sanofi-Synthélabo merged with Aventis and renamed to Sanofi-Aventis, which were each the product of several previous mergers ...
This template's initial visibility currently defaults to autocollapse, meaning that if there is another collapsible item on the page (a navbox, sidebar, or table with the collapsible attribute), it is hidden apart from its title bar; if not, it is fully visible. To change this template's initial visibility, the |state= parameter may be used:
Rhône-Poulenc (French pronunciation: [ʁon pulɛ̃k]) was a French chemical and pharmaceutical company founded in 1928.In 1999, it merged with Hoechst AG to form Aventis.As of 2015, the pharmaceutical operations of Rhône-Poulenc are part of Sanofi and the chemicals divisions are part of Solvay group and Bayer Crop Science.
Roussel Uclaf S.A. was a French pharmaceutical company and one of several predecessor companies of today's Sanofi. It was the second largest French pharmaceutical company [6] before it was acquired by Hoechst AG of Frankfurt, Germany in 1997, with pharmaceutical operations combined into the Hoechst Marion Roussel (HMR) division in the United States.
The former Hoechst AG and today's Industriepark Höchst. Hoechst AG (German pronunciation: [ˈhøːçst]) was a German chemicals, later life sciences, company that became Aventis Deutschland after its merger with France's Rhône-Poulenc S.A. in 1999.
Formulated as a tablet and as sachets of a water-soluble powder, it is sold under the trade name Paramax by Sanofi-Synthelabo, [1] and in Switzerland as Migraeflux MCP, [2] in Australia it is sold as Meteclomax and Anagraine.